Corbus Pharmaceuticals Holdings will host a conference call webcast on Monday, September 14, 2026, at 8:00 a.m. EDT to discuss topline data from CANYON-1, a Phase 1b obesity study of CRB-913. The 16-week, double-blind, placebo-controlled, dose-ranging trial enrolled 240 obese, non-diabetic adults at multiple U.S. sites and is registered as NCT07310901. CRB-913 is a once-daily oral CB1 inverse agonist, a compound designed to block cannabinoid receptor activity, with limited penetration beyond peripheral tissues. The trial tested 20 mg, 40 mg and 60 mg cohorts against placebo, using dose titration and 12 weeks of treatment followed by four weeks of safety monitoring. Harold Bays, M.D., an investigator in the study, will join the event as a guest speaker. A replay will be posted on Corbus' website. Corbus is also developing CRB-701, an antibody-drug conjugate for Nectin-4-expressing tumors. The release includes customary forward-looking statement warnings covering clinical results, development and regulatory timelines, market opportunity, operations, cash runway and other risks described in the company's Securities and Exchange Commission filings.